{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:46:04Z","timestamp":1791751564112,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["TBI-V-1-356-VBU-123"],"award-info":[{"award-number":["TBI-V-1-356-VBU-123"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.cca.2026.122866","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:00:05Z","timestamp":1790866805000},"page":"122866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Performance assessment of a novel fully automated ELISA for anti-IA2 autoantibody detection in type 1 diabetes"],"prefix":"10.1016","volume":"594","author":[{"given":"Martina","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia-Gia Toni","family":"H\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9859-8263","authenticated-orcid":false,"given":"Petra","family":"Augstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2081-6090","authenticated-orcid":false,"given":"Malgorzata","family":"Baranowska-Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"D\u00e4hnrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Deerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4769-915X","authenticated-orcid":false,"given":"Sandra","family":"Saschenbrecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4785-6682","authenticated-orcid":false,"given":"Wolfgang","family":"Kerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-3316","authenticated-orcid":false,"given":"Lars","family":"Komorowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-8631","authenticated-orcid":false,"given":"Alexander","family":"K\u00fchnl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7115-2122","authenticated-orcid":false,"given":"Kai","family":"Masur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-8482","authenticated-orcid":false,"given":"Christian","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Rhein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-9935","authenticated-orcid":false,"given":"Skander","family":"Elleuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.122866_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.cca.2026.122866_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3770","article-title":"Type 1 diabetes: a new vision of the disease based on endotypes","volume":"40","author":"Weston","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"10","key":"10.1016\/j.cca.2026.122866_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2025.109132","article-title":"What type 1 diabetes endotype is most suitable for anti-CD3 antibodies prevention trials?","volume":"39","author":"Wilson","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.cca.2026.122866_bb0020","article-title":"From disease and patient heterogeneity to precision medicine in type 1 diabetes","volume":"9","author":"den Hollander","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cca.2026.122866_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112277","article-title":"Global type 1 diabetes prevalence, incidence, and mortality estimates 2025: results from the International Diabetes Federation Atlas, 11th edition, and the T1D Index version 3.0","volume":"225","author":"Ogle","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0030","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2026.0048","article-title":"Type 1 diabetes: a review","volume":"335","author":"Jacobsen","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2026.122866_bb0035","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"Supplement 1","key":"10.1016\/j.cca.2026.122866_bb0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes - 2026","volume":"49","author":"American Diabetes Association (ADA), Professional Practice Committee. 2","year":"2026","journal-title":"Diabetes Care"},{"issue":"7892","key":"10.1016\/j.cca.2026.122866_bb0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(74)90140-8","article-title":"Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies","volume":"2","author":"Bottazzo","year":"1974","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210012","article-title":"Anti-islet autoantibodies in type 1 diabetes","volume":"24","author":"Kawasaki","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4630","key":"10.1016\/j.cca.2026.122866_bb0055","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.6362005","article-title":"Insulin antibodies in insulin-dependent diabetics before insulin treatment","volume":"222","author":"Palmer","year":"1983","journal-title":"Science"},{"issue":"6289","key":"10.1016\/j.cca.2026.122866_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/347151a0","article-title":"Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase","volume":"347","author":"Baekkeskov","year":"1990","journal-title":"Nature"},{"issue":"31","key":"10.1016\/j.cca.2026.122866_bb0065","doi-asserted-by":"crossref","first-page":"21257","DOI":"10.1016\/S0021-9258(18)54849-3","article-title":"Pancreatic beta cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kDa hydrophilic form and a 64-kDa amphiphilic form which can be both membrane-bound and soluble","volume":"266","author":"Christgau","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cca.2026.122866_bb0070","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/j.1460-2075.1996.tb00564.x","article-title":"ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules","volume":"15","author":"Solimena","year":"1996","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.cca.2026.122866_bb0075","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.93.13.6367","article-title":"IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus","volume":"93","author":"Lan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"43","key":"10.1016\/j.cca.2026.122866_bb0080","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0085","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0090","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00125-023-06004-4","article-title":"The challenges of identifying and studying type 1 diabetes in adults","volume":"66","author":"Thomas","year":"2023","journal-title":"Diabetologia"},{"issue":"23","key":"10.1016\/j.cca.2026.122866_bb0095","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0100","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad160","article-title":"Understanding islet autoantibodies in prediction of type 1 diabetes","volume":"8","author":"Jia","year":"2024","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-088522","article-title":"EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents","volume":"15","author":"Hoffmann","year":"2025","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cca.2026.122866_bb0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1172\/JCI119879","article-title":"Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The childhood diabetes in Finland study group","volume":"101","author":"Kulmala","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"24","key":"10.1016\/j.cca.2026.122866_bb0115","doi-asserted-by":"crossref","first-page":"8704","DOI":"10.1073\/pnas.0408887102","article-title":"The dense core transmembrane vesicle protein IA-2 is a regulator of vesicle number and insulin secretion","volume":"102","author":"Harashima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cca.2026.122866_bb0120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/dna.1994.13.505","article-title":"Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma","volume":"13","author":"Lan","year":"1994","journal-title":"DNA Cell Biol."},{"issue":"8","key":"10.1016\/j.cca.2026.122866_bb0125","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/diab.46.8.1270","article-title":"Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes","volume":"46","author":"Hawa","year":"1997","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.cca.2026.122866_bb0130","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2337\/diab.46.11.1701","article-title":"Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers","volume":"46","author":"Bingley","year":"1997","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/jdi.13910","article-title":"Comparing the clinical significance and antigen specificity of insulinoma-associated antigen-2 autoantibodies between radioimmunoassay and enzyme-linked immunosorbent assay in Japanese patients with type 1 diabetes","volume":"14","author":"Kawasaki","year":"2023","journal-title":"J. Diabetes Investig."},{"issue":"2","key":"10.1016\/j.cca.2026.122866_bb0140","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s13410-020-00882-9","article-title":"Prevalence of IA-2 antibody in patients suffering from diabetes and their first-degree relatives","volume":"41","author":"Bolandi","year":"2021","journal-title":"Int. J. Diabetes Dev. Ctries."},{"issue":"5","key":"10.1016\/j.cca.2026.122866_bb0145","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00125-025-06382-x","article-title":"IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes","volume":"68","author":"Sims","year":"2025","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.cca.2026.122866_bb0150","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2337\/dc14-2426","article-title":"Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the Environmental Determinants of Diabetes in the Young (TEDDY)","volume":"38","author":"Steck","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.cca.2026.122866_bb0155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/jaut.1999.0281","article-title":"Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives","volume":"12","author":"Maclaren","year":"1999","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.cca.2026.122866_bb0160","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/diabetes.53.2.384","article-title":"Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics","volume":"53","author":"Achenbach","year":"2004","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.cca.2026.122866_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S2352-4642(22)00350-9","article-title":"Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study","volume":"7","author":"Ghalwash","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"issue":"3","key":"10.1016\/j.cca.2026.122866_bb0170","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/dci25-0066","article-title":"Toward disease-modifying therapies in type 1 diabetes: focus on teplizumab","volume":"49","author":"Mathieu","year":"2026","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.cca.2026.122866_bb0175","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-8587(22)00141-3","article-title":"Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study","volume":"10","author":"Ghalwash","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.cca.2026.122866_bb0180","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2337\/dc20-1836","article-title":"Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S","volume":"44","author":"Anand","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0185","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/clinem\/dgad328","article-title":"Screening and prevention of type 1 diabetes: where are we?","volume":"108","author":"Simmons","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.cca.2026.122866_bb0190","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00125-023-05953-0","article-title":"Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation","volume":"66","author":"Hummel","year":"2023","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.cca.2026.122866_bb0195","first-page":"1276","article-title":"Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes","volume":"47","author":"Phillip","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2026.122866_bb0200","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/7651_2015_292","article-title":"Islet autoantibody analysis: radioimmunoassays","volume":"1433","author":"Wyatt","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.cca.2026.122866_bb0205","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1515\/cclm-2025-0238","article-title":"A comparison of current methods to measure antibodies in type 1 diabetes","volume":"63","author":"Infantino","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.122866_bb0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/jlpm.2019.09.03","article-title":"Evaluation of precision, comparability and linearity of MAGLUMI\u2122 2000 plus GAD65 antibody assay","volume":"4","author":"Cosma","year":"2019","journal-title":"J. Lab. Precis. Med."},{"issue":"13","key":"10.1016\/j.cca.2026.122866_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15131695","article-title":"A comparative evaluation of the chemiluminescence immunoassay and ELISA for the detection of islet autoantibodies in type 1 diabetes","volume":"15","author":"Danese","year":"2025","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cccn.2005.02.006","article-title":"Sensitive non-isotopic assays for autoantibodies to IA-2 and to a combination of both IA-2 and GAD65","volume":"357","author":"Chen","year":"2005","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.122866_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2025.113885","article-title":"Development and performance evaluation of a novel, fully automated, high-throughput GAD65 autoantibody assay on the Phadia platform","volume":"542","author":"Filchtinski","year":"2025","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cca.2026.122866_bb0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cca.2015.05.010","article-title":"Bridging-type enzyme-linked immunoassay for zinc transporter 8 autoantibody measurements in adult patients with diabetes mellitus","volume":"447","author":"Dunseath","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.122866_bb0235","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cca.2016.08.013","article-title":"3 screen islet cell autoantibody ELISA: a sensitive and specific ELISA for the combined measurement of autoantibodies to GAD(65), to IA-2 and to ZnT8","volume":"462","author":"Amoroso","year":"2016","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.cca.2026.122866_bb0240","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00592-022-01856-5","article-title":"Evaluation of the RSR 3 screen ICA and 2 screen ICA as screening assays for type 1 diabetes in Sweden","volume":"59","author":"T\u00f6rn","year":"2022","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.cca.2026.122866_bb0245","unstructured":"G.G.T. H\u00f2, M. Lehmann, P. Augstein, M. Baranowska-Dell, C. D\u00e4hnrich, A. Deerberg, S. Saschenbrecker, W. Kerner, L. Komorowski, A. K\u00fchnl, K. Masur, C. Probst, S. Rhein, M. Schlosser, S. Elleuche, Evaluation of a new ELISA for fully automated detection of anti-GAD autoantibodies in type 1 diabetes and anti-GAD-associated neurological diseases, 2026. Manuscript under review."},{"key":"10.1016\/j.cca.2026.122866_bb0250","unstructured":"EUROIMMUN Medizinische Labordiagnostika AG, EU Declaration of Conformity: Anti-IA2 ELISA (EA_1023\u20139601-2). Available from: https:\/\/certificates.euroimmun.de\/en, 2024 (accessed 14 September 2026)."},{"issue":"01","key":"10.1016\/j.cca.2026.122866_bb0255","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0042-100779","article-title":"Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. S3-Leitlinie der DDG und AGDP 2015. AWMF-Registernummer 057\u2013016","volume":"11","author":"Neu","year":"2016","journal-title":"Diabetol. Stoffwechs."},{"issue":"05","key":"10.1016\/j.cca.2026.122866_bb0260","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/a-0666-0820","article-title":"S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. AWMF-Registernummer 057\u2013017","volume":"13","author":"Bahrmann","year":"2018","journal-title":"Diabetol. Stoffwechs."},{"key":"10.1016\/j.cca.2026.122866_bb0265","unstructured":"Deutsche Diabetes Gesellschaft (DDG). S3-Leitlinie Therapie des Typ-1 Diabetes, 2. Auflage. AWMF-Registernummer 057\u2013013. DDG, Berlin, Germany, 2018. Available from: https:\/\/www.ddg.info\/fileadmin\/user_upload\/05_Behandlung\/01_Leitlinien\/Evidenzbasierte_Leitlinien\/2018\/S3-LL-Therapie-Typ-1-Diabetes-Auflage-2-Langfassung-09042018.pdf (accessed 14 September 2026)."},{"key":"10.1016\/j.cca.2026.122866_bb0270","unstructured":"IDS (Immunology of Diabetes Society) IASP\/DASP Autoantibody Workshops. Available from: https:\/\/www.immunologyofdiabetessociety.com\/iasp-dasp-autoantibody-workshops\/ (accessed 14 September 2026)."},{"key":"10.1016\/j.cca.2026.122866_bb0275","unstructured":"EUROIMMUN Medizinische Labordiagnostika AG, Instructions for Use: Anti-IA2 ELISA (EA_1023\u20139601-2), 2025. Available from: https:\/\/products.euroimmun.de\/#\/login (accessed 14 September 2026)."},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0280","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5455\/aim.2016.24.61-65","article-title":"ELISA test for analyzing of incidence of type 1 diabetes autoantibodies (GAD and IA2) in children and adolescents","volume":"24","author":"Delic-Sarac","year":"2016","journal-title":"Acta Inform. Med."},{"key":"10.1016\/j.cca.2026.122866_bb0285","unstructured":"EUROIMMUN Medizinische Labordiagnostika AG Instructions for Use: Anti-IA2 ELISA (IgG) (EA_1023\u20139601 G), 2022. Available from: https:\/\/products.euroimmun.de\/#\/login (accessed 14 September 2026)."},{"key":"10.1016\/j.cca.2026.122866_bb0290","unstructured":"Medipan GmbH. Instructions for Use: CentAK anti-IA2 M (REF 2050), 2022. Available from: https:\/\/www.medipan.de\/sdm_categories\/ifu\/, 2022 (accessed 14 September 2026)."},{"key":"10.1016\/j.cca.2026.122866_bb0295","series-title":"Evaluation of Precision of Quantitative Measurement Procedures","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2014"},{"key":"10.1016\/j.cca.2026.122866_bb0300","series-title":"Evaluation of Detection Capability for Laboratory Measurement Procedures","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"issue":"11","key":"10.1016\/j.cca.2026.122866_bb0305","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1023\/B:PHAM.0000003390.51761.3d","article-title":"Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules","volume":"20","author":"DeSilva","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cca.2026.122866_bb0310","series-title":"Bioanalytical Method Validation: Guidance for Industry","author":"U.S. Food and Drug Administration (FDA)","year":"2018"},{"key":"10.1016\/j.cca.2026.122866_bb0315","series-title":"Evaluation of the Linearity of Quantitative Measurement Procedures","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2003"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0320","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1208\/s12248-013-9542-y","article-title":"Large molecule specific assay operation: recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team","volume":"16","author":"Stevenson","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.cca.2026.122866_bb0325","series-title":"Interference Testing in Clinical Chemistry","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.cca.2026.122866_bb0330","article-title":"Evaluation of analytical performances of magnetic force-assisted electrochemical sandwich immunoassay for the quantification of carcinoembryonic antigen","volume":"9","author":"Hwang","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0335","doi-asserted-by":"crossref","first-page":"23884","DOI":"10.1038\/s41598-024-76023-7","article-title":"ELISA genotyping of hepatitis B virus in China with antibodies specific for genotypes B and C","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.122866_bb0340","series-title":"Statistics with Confidence: Confidence Intervals and Statistical Guidelines","author":"Altman","year":"2000"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0345","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.cca.2026.122866_bb0350","series-title":"Statistical Methods for Rates and Proportions","author":"Fleiss","year":"2003"},{"issue":"2","key":"10.1016\/j.cca.2026.122866_bb0355","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/cei\/uxac087","article-title":"The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants","volume":"210","author":"Williams","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cca.2026.122866_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.815703","article-title":"The prevalence of islet autoantibodies in children and adolescents with type 1 diabetes mellitus: a global scoping review","volume":"13","author":"Ross","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0365","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc21-0878","article-title":"Islet autoantibody type-specific titer thresholds improve stratification of risk of progression to type 1 diabetes in children","volume":"45","author":"Ng","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cca.2026.122866_bb0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1749-6632.2002.tb02978.x","article-title":"Autoantibodies to IA-2 in type 1 diabetes: measurements with a new enzyme-linked immunosorbent assay","volume":"958","author":"Kawasaki","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.cca.2026.122866_bb0375","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.152.6.3183","article-title":"Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases","volume":"152","author":"Rabin","year":"1994","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.122866_bb0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s001250050648","article-title":"IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry","volume":"40","author":"Gorus","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.cca.2026.122866_bb0385","doi-asserted-by":"crossref","first-page":"16275","DOI":"10.18632\/oncotarget.24527","article-title":"Autoantibodies against islet cell antigens in children with type 1 diabetes mellitus","volume":"9","author":"Cheng","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.122866_bb0390","doi-asserted-by":"crossref","unstructured":"K. Savola, E. Bonifacio, E. Sabbah, P. Kulmala, P. V\u00e4h\u00e4salo, J. Karjalainen, E. Tuomilehto-Wolf, J. Meril\u00e4inen, H.K. \u00c5kerblom, M. Knip, G. Childhood diabetes Finland study, IA-2 antibodies \u2013 a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41 (4) (1998) 424\u2013429. Doi: https:\/\/doi.org\/10.1007\/s001250050925.","DOI":"10.1007\/s001250050925"},{"issue":"12","key":"10.1016\/j.cca.2026.122866_bb0395","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1515\/cclm-2025-0137","article-title":"Method comparison of diabetes mellitus associated autoantibodies in serum specimens","volume":"63","author":"Lenard","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"issue":"4","key":"10.1016\/j.cca.2026.122866_bb0400","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/dom.13595","article-title":"Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide survey","volume":"21","author":"Xiang","year":"2019","journal-title":"Diabetes Obes. Metab."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126020486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:58:09Z","timestamp":1791748689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126020486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":80,"alternative-id":["S0009898126020486"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.122866","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance assessment of a novel fully automated ELISA for anti-IA2 autoantibody detection in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.122866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122866"}}